Obermatt
See Similar Stocks →

Innate Pharma

PAR:IPH · FR0010331421
BiotechnologySmall

360

54
Profit price61
Owner Earnings Yield1
Dividend Yield1
Price/Sales59
Price/Book53
Returns on capital7
Profit margins10
Accruals40
Owner Earnings Margin42
Sales growth86
Profit growth46
Reinvestment95
Price momentum25
Debt load1
Refinancing12
Debt Payback1
Liquidity15
Analyst ratings100
Opinion Changes50
Price Target Upside97
Market mood41
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Innate Pharma doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryFrance
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeENXTPA
Founded1999
Employees175
Websiteinnate-pharma.com
ISINFR0010331421
Last UpdateApr 2, 2026
Indices
CAC All (France)NASDAQ (USA)
Themes
HematologyImmunologyOncologyBiopharmaBiotechnologyClinical TrialsMedicalPharmaceutical

Description

Innate Pharma S.A. (Innate Pharma or Innate), a clinical-stage biotechnology company, develops immunotherapies for cancer patients. Leveraging the company’s expertise on antibody-engineering and innovative target identification, the company is devel…

Analysis

Middle-of-the-road

Innate Pharma S.A. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is adequate. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
40
2026

All-time high

40

Jun 2026

All-time low

6

Mar 2026

Average rank

23

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
59
—
—
—
Price/Earnings
53
—
—
—
Price/Book
53
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
61
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Innate Pharma with its peers
Galapagos
AEX:GLPG
76
CountryBelgium
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Transgene
PAR:TNG
15
CountryFrance
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Immunovant
NSQ:IMVT
86
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kiniksa Pharmaceuticals
NSQ:KNSA
99
CountryUK
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
OSE Immunotherapeutics
PAR:OSE
31
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Prothena Corporation
NSQ:PRTA
39
CountryIreland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →